Induction therapy in renal transplant recipients: A review

Mark Reza Laftavi, Rajeev Sharma, Lin Feng, Meriem Said, Oleh Pankewycz

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Transplant science has improved significantly over the last decade. Influenced by novel advancements, rejection rates and short-term graft losses diminished substantially. Induction therapy was shown to reduce rejection rates and improve short-term graft survival. In this article, we discuss the most commonly used induction agents and the choice of induction therapy in different renal transplant recipient subgroups. The medical literature as well as our own experience was used to prepare this review. At this time, induction therapy is commonly used in upwards of 80%, of renal transplant recipients. Depleting agents are the most frequently used agents and they account for more than 75% of all induction therapies in the United States. Currently, there is no consensus regarding the choice of induction therapy. The type of induction therapy is generally selected based on a comprehensive evaluation of the recipient and the donor's immunological risks, the risk of developing opportunistic infection and malignancy, recipient comorbidities, financial burden and the choice of maintenance immunosuppressive regimen.

Original languageEnglish (US)
Pages (from-to)790-806
Number of pages17
JournalImmunological Investigations
Volume43
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Kidney
Therapeutics
Transplants
Opportunistic Infections
Graft Survival
Immunosuppressive Agents
Transplant Recipients
Comorbidity
Maintenance
Tissue Donors
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Laftavi, M. R., Sharma, R., Feng, L., Said, M., & Pankewycz, O. (2014). Induction therapy in renal transplant recipients: A review. Immunological Investigations, 43(8), 790-806. https://doi.org/10.3109/08820139.2014.914326
Laftavi, Mark Reza ; Sharma, Rajeev ; Feng, Lin ; Said, Meriem ; Pankewycz, Oleh. / Induction therapy in renal transplant recipients : A review. In: Immunological Investigations. 2014 ; Vol. 43, No. 8. pp. 790-806.
@article{e5df1dbd1e5242f3acc7aebf7a6f47ca,
title = "Induction therapy in renal transplant recipients: A review",
abstract = "Transplant science has improved significantly over the last decade. Influenced by novel advancements, rejection rates and short-term graft losses diminished substantially. Induction therapy was shown to reduce rejection rates and improve short-term graft survival. In this article, we discuss the most commonly used induction agents and the choice of induction therapy in different renal transplant recipient subgroups. The medical literature as well as our own experience was used to prepare this review. At this time, induction therapy is commonly used in upwards of 80{\%}, of renal transplant recipients. Depleting agents are the most frequently used agents and they account for more than 75{\%} of all induction therapies in the United States. Currently, there is no consensus regarding the choice of induction therapy. The type of induction therapy is generally selected based on a comprehensive evaluation of the recipient and the donor's immunological risks, the risk of developing opportunistic infection and malignancy, recipient comorbidities, financial burden and the choice of maintenance immunosuppressive regimen.",
author = "Laftavi, {Mark Reza} and Rajeev Sharma and Lin Feng and Meriem Said and Oleh Pankewycz",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/08820139.2014.914326",
language = "English (US)",
volume = "43",
pages = "790--806",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "8",

}

Laftavi, MR, Sharma, R, Feng, L, Said, M & Pankewycz, O 2014, 'Induction therapy in renal transplant recipients: A review', Immunological Investigations, vol. 43, no. 8, pp. 790-806. https://doi.org/10.3109/08820139.2014.914326

Induction therapy in renal transplant recipients : A review. / Laftavi, Mark Reza; Sharma, Rajeev; Feng, Lin; Said, Meriem; Pankewycz, Oleh.

In: Immunological Investigations, Vol. 43, No. 8, 01.01.2014, p. 790-806.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Induction therapy in renal transplant recipients

T2 - A review

AU - Laftavi, Mark Reza

AU - Sharma, Rajeev

AU - Feng, Lin

AU - Said, Meriem

AU - Pankewycz, Oleh

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Transplant science has improved significantly over the last decade. Influenced by novel advancements, rejection rates and short-term graft losses diminished substantially. Induction therapy was shown to reduce rejection rates and improve short-term graft survival. In this article, we discuss the most commonly used induction agents and the choice of induction therapy in different renal transplant recipient subgroups. The medical literature as well as our own experience was used to prepare this review. At this time, induction therapy is commonly used in upwards of 80%, of renal transplant recipients. Depleting agents are the most frequently used agents and they account for more than 75% of all induction therapies in the United States. Currently, there is no consensus regarding the choice of induction therapy. The type of induction therapy is generally selected based on a comprehensive evaluation of the recipient and the donor's immunological risks, the risk of developing opportunistic infection and malignancy, recipient comorbidities, financial burden and the choice of maintenance immunosuppressive regimen.

AB - Transplant science has improved significantly over the last decade. Influenced by novel advancements, rejection rates and short-term graft losses diminished substantially. Induction therapy was shown to reduce rejection rates and improve short-term graft survival. In this article, we discuss the most commonly used induction agents and the choice of induction therapy in different renal transplant recipient subgroups. The medical literature as well as our own experience was used to prepare this review. At this time, induction therapy is commonly used in upwards of 80%, of renal transplant recipients. Depleting agents are the most frequently used agents and they account for more than 75% of all induction therapies in the United States. Currently, there is no consensus regarding the choice of induction therapy. The type of induction therapy is generally selected based on a comprehensive evaluation of the recipient and the donor's immunological risks, the risk of developing opportunistic infection and malignancy, recipient comorbidities, financial burden and the choice of maintenance immunosuppressive regimen.

UR - http://www.scopus.com/inward/record.url?scp=84911074397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911074397&partnerID=8YFLogxK

U2 - 10.3109/08820139.2014.914326

DO - 10.3109/08820139.2014.914326

M3 - Review article

C2 - 25296234

AN - SCOPUS:84911074397

VL - 43

SP - 790

EP - 806

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 8

ER -